CoChat

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients.Methods For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652.Findings Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months' median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients.Interpretation Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.Funding F Hoffmann-La Roche, Genentech.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)32455-2

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 2,199

Metadata

Authors
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., Dawson, N. A., van der Heijden, M. S., Dreicer, R., Srinivas, S., Retz, M. M., Joseph, R. W., Drakaki, A., Vaishampayan, U. N., Sridhar, S. S., Quinn, D. I., Durán, I., Shaffer, D. R., Eigl, B. J., Grivas, P. D., Yu, E. Y., Li, S., Kadel, E. E., Boyd, Z., Bourgon, R., Hegde, P. S., Mariathasan, S., Thåström, A., Abidoye, O. O., Fine, G. D., & Bajorin, D. F.
Affiliations
  • NYU Langone Health (US)
  • Tisch Cancer Institute (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Queen Mary University of London (GB)
  • Yale University (US)
  • Université Paris-Saclay (FR)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Sidney Kimmel Cancer Center (US)
  • MedStar Georgetown University Hospital (US)
  • University of Virginia (US)
  • Stanford Medicine (US)
  • TUM Klinikum (DE)
  • Mayo Clinic (US)
  • University of California, Los Angeles (US)
  • Wayne State University (US)
  • Princess Margaret Cancer Centre (CA)
  • USC Norris Comprehensive Cancer Center (US)
  • Instituto de Biomedicina de Sevilla (ES)
  • New York Oncology Hematology (US)
  • BC Cancer Agency (CA)
  • Cleveland Clinic (US)
  • University of Washington (US)
  • Genentech (US)
Corresponding author
Balar, Arjun V
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-01
Volume
389
Issue
10064
Pages
67-76
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2559804019
Cited by
2,199
References
29
Citations by year
2026: 83 · 2025: 166 · 2024: 206 · 2023: 258 · 2022: 263 · 2021: 294 · 2020: 280 · 2019: 241 · 2018: 247 · 2017: 152
FWCI
238.54
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Celgene
  • F. Hoffmann-La Roche
  • Eisai
  • Astellas Pharma
  • Ipsen
  • Genentech
  • EMD Serono
  • National Cancer Institute (P30CA008748, P30CA015083)
Topics
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords
atezolizumab, urothelial carcinoma, metastatic urothelial carcinoma, locally advanced urothelial carcinoma, cisplatin-ineligible patients, PD-L1 inhibitors, first-line therapy, objective response rate, PD-L1 expression, progression-free survival, overall survival, immune-related adverse events, sepsis, non-relapse mortality
MeSH terms
Contraindications, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Transitional Cell, Cisplatin, Female, Humans, Infusions, Intravenous, Lymphatic Metastasis, Male, Middle Aged, Biomarkers, Tumor, Urologic Neoplasms, Kaplan-Meier Estimate, B7-H1 Antigen, Antibodies, Monoclonal, Humanized, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.